Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 0 Study Using the CIVO® Platform to Evaluate Intratumoral Microdoses of Motolimod Singly and in Combination With Nivolumab in Patients With Head and Neck Cancer

NCT04272333 is registered in ClinicalTrials.gov with Presage Biosciences as lead sponsor.

NCT NCT04272333
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04272333 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 0 Study Using the CIVO® Platform to Evaluate Intratumoral Microdoses of Motolimod Singly and in Combination With Nivolumab in Patients With Head and Neck Cancer
Lead sponsor
Presage Biosciences
Phase
Phase 1
Overall status
Terminated
Start date
October 15, 2021
Completion date
March 25, 2022
Enrollment
1 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

hnscc